Joel Greenblatt, the founder of the $6.8 billion Gotham Asset Management fund, has signaled a cautious sentiment towards two-mega cap pharma stocks. In the third quarter, Greenblatt slashed the fund’s holding of both Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Gilead Sciences, Inc. (NASDAQ:GILD). His moves are closely followed by traders all over the world, keen for an insight into how one…
Discover more from USNewsRank
Subscribe to get the latest posts sent to your email.